Latest Safety News

Biotron Limited has closed its non-renounceable rights issue, raising $645,861 to advance its Hepatitis B virus drug development, with a shortfall commitment from Peak Asset Management still pending.

Downer EDI Limited has been named preferred contractor for four major New Zealand state highway maintenance contracts, securing an estimated NZD 870 million in revenue over initial contract periods starting May 2026.

Scout Security outlines a bold transformation with the acquisition of Roo Inc., expansion into insuretech, and a pivot to AI-driven smart security solutions, positioning itself for accelerated growth and profitability.

Imricor Medical Systems has secured Charité University Hospital in Berlin as the second global site for its VISABL-VT clinical trial, marking a significant milestone in real-time MRI-guided cardiac ablation technology.

PYC Therapeutics reports positive safety outcomes from the initial phase of its clinical trial for PYC-003, a promising treatment for Polycystic Kidney Disease. The drug was well tolerated in healthy volunteers, paving the way for patient dosing and further trials.

Sparc Technologies has achieved a significant commercial milestone with its first sale of ecosparc®, a graphene-based additive for protective coatings, to an Asian coatings company following successful proof-of-concept testing.

Alligator Energy has successfully completed the construction of its Samphire Uranium Project pilot plant, achieving practical completion safely, on schedule, and under budget. The company is now set to begin its Field Recovery Trial in early 2026, marking a pivotal step toward project development.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

KGL Resources has appointed Sam Strohmayr as its new CEO, bringing deep global mining expertise, while also establishing a new operations office in Darwin to bolster stakeholder engagement.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

RocketDNA has secured approximately A$1 million in new orders from major mining clients, expanding its autonomous drone deployments and software services across Australia and Africa.